Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1948 5
1949 3
1950 1
1951 3
1952 5
1953 4
1954 1
1955 4
1956 3
1957 2
1958 1
1959 1
1960 1
1961 1
1962 2
1966 1
1968 2
1972 1
1973 1
1974 2
1975 1
1976 1
1977 1
1979 1
1980 1
1981 2
1982 8
1983 6
1984 7
1985 5
1986 13
1987 9
1988 8
1989 10
1990 16
1991 12
1992 15
1993 12
1994 18
1995 30
1996 27
1997 22
1998 15
1999 35
2000 31
2001 35
2002 40
2003 28
2004 35
2005 48
2006 51
2007 42
2008 55
2009 46
2010 62
2011 79
2012 75
2013 95
2014 95
2015 88
2016 104
2017 102
2018 124
2019 113
2020 127
2021 137
2022 119
2023 112
2024 123
2025 110
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,119 results

Results by year

Filters applied: . Clear all
Page 1
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: bauer tm. J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31. J Clin Oncol. 2024. PMID: 38819031 Free PMC article. Clinical Trial.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. Among authors: bauer tm. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.
Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E. Altorki N, et al. Among authors: bauer t. N Engl J Med. 2023 Feb 9;388(6):489-498. doi: 10.1056/NEJMoa2212083. N Engl J Med. 2023. PMID: 36780674 Free PMC article. Clinical Trial.
RpoS and the bacterial general stress response.
Bouillet S, Bauer TS, Gottesman S. Bouillet S, et al. Among authors: bauer ts. Microbiol Mol Biol Rev. 2024 Mar 27;88(1):e0015122. doi: 10.1128/mmbr.00151-22. Epub 2024 Feb 27. Microbiol Mol Biol Rev. 2024. PMID: 38411096 Free PMC article. Review.
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: bauer tm. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Wirth LJ, et al. Among authors: bauer tm. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651. N Engl J Med. 2020. PMID: 32846061 Free PMC article. Clinical Trial.
Macrophage-specific inhibition of the histone demethylase JMJD3 decreases STING and pathologic inflammation in diabetic wound repair.
Audu CO, Melvin WJ, Joshi AD, Wolf SJ, Moon JY, Davis FM, Barrett EC, Mangum KD, Deng H, Xing X, Wasikowski R, Tsoi LC, Sharma SB, Bauer TM, Shadiow J, Corriere MA, Obi AT, Kunkel SL, Levi B, Moore BB, Gudjonsson JE, Smith AM, Gallagher KA. Audu CO, et al. Among authors: bauer tm. Cell Mol Immunol. 2022 Nov;19(11):1251-1262. doi: 10.1038/s41423-022-00919-5. Epub 2022 Sep 20. Cell Mol Immunol. 2022. PMID: 36127466 Free PMC article.
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Solomon BJ, et al. Among authors: bauer tm. J Clin Oncol. 2022 Nov 1;40(31):3593-3602. doi: 10.1200/JCO.21.02278. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605188 Free PMC article. Clinical Trial.
2,119 results